

Application No. 09/923,270
Amdt. dated March 21, 2005
Reply to Final Office Action of August 24, 2004

Amendments to the Claims:

1-12. (Cancelled)

13. (Currently Amended) ~~An A~~ A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence comprising and an AAV helper virus nucleic acid sequence for developing AAV viral particles, wherein said AAV helper virus sequence comprises the complete adenovirus 5 sequence with exception of the E1 region.

14. (Currently Amended) ~~An A~~ A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence comprising and an AAV helper virus nucleic acid sequence for developing AAV viral particles, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248.

15. (Currently Amended) ~~An A~~ A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence comprising and an AAV helper virus nucleic acid sequence for developing AAV viral particles, wherein said ~~nucleic acid~~ AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of ~~the~~ L1 and E1 regions.

16. (Currently Amended) ~~An A~~ A nucleic acid sequence comprising an adeno-associated virus (AAV) nucleic acid sequence comprising and an AAV helper virus nucleic acid sequence for developing AAV viral particles, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817.

17. (Currently Amended) A composition comprising ~~the a~~ a nucleic acid sequence of Claim 13, 14, 15, or 16, and ~~an~~ rAAV vector.

Application No. 09/923,270
Amdt. dated March 21, 2005
Reply to Final Office Action of August 24, 2004

18. (Previously Presented) The composition of Claim 17, further comprising a cell.
19. (Previously Presented) The composition of Claim 18, wherein said cell is a mammalian cell.
20. (Currently Amended) A method for producing ~~an~~ rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to ~~an AAV~~ a nucleic acid sequence comprising an AAV nucleic acid sequence and an AAV helper virus nucleic acid sequence for developing AAV viral particles, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the E1 region;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
21. (Currently Amended) A method for producing ~~an~~ rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to ~~an AAV~~ a nucleic acid sequence comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248;
 - b) inducing said cells to develop rAAV viral particles; and
 - c) isolating said rAAV viral particles.
22. (Currently Amended) A method for producing ~~an~~ rAAV viral particle preparation which is not contaminated with helper viruses, comprising:
- a) exposing cells to ~~an AAV~~ a nucleic acid sequence comprising an AAV nucleic acid sequence and an AAV helper virus nucleic acid sequence developing AAV viral

Application No. 09/923,270
Amdt. dated March 21, 2005
Reply to Final Office Action of August 24, 2004

particles, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the L1 and the E1 regions;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

23. (Currently Amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- a) exposing cells to a nucleic acid sequence comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817;
- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

24. (Currently Amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- a) exposing cells to a composition comprising (1) a nucleic acid sequence comprising an AAV virus nucleic acid sequence and an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the E1 region, and (2) an rAAV vector;
- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

25. (Currently Amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- a) exposing cells to a composition comprising (1) an AAV helper virus a nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence has

Application No. 09/923,270
Amdt. dated March 21, 2005
Reply to Final Office Action of August 24, 2004

been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11248 and (2) an rAAV vector;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

26. (Currently Amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) a nucleic acid sequence comprising an AAV nucleic acid sequence and an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said AAV helper virus nucleic acid sequence comprises the complete adenovirus 5 sequence with exception of the L1 and the E1 regions and (2) an rAAV vector;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.

27. (Currently Amended) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

a) exposing cells to a composition comprising (1) ~~an AAV helper virus~~ a nucleic acid sequence ~~developing AAV viral particles~~, wherein said nucleic acid sequence has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSMZ 11817 and (2) an rAAV vector;

- b) inducing said cells to develop rAAV viral particles; and
- c) isolating said rAAV viral particles.